From our December 2019 Newsletter

NEWS AND ANNOUNCEMENTS

1. WHO announces changes to the treatment of drug-resistant tuberculosis
Significant improvements in treatment outcomes and quality of life for patients with drug-resistant tuberculosis (TB) are expected, following key updates to treatment approaches, announced by WHO.
2. TB Alliance responds to questions raised by activists in relation to pretomanid
MSF, TAG and TB CAB raised a number of outstanding medical and research questions regarding pretomanid and the regimen BPaL.
3. Save the Date! RESIST-TB will be hosting a webinar in the new year!
Mark your calendar for Monday, January 27th from 08:00 to 9:00 EST (13:00-14:00 CET) for a presentation from Molly Franke, ScD, Associate Professor of Global Health and Social Medicine, Harvard Medical School, and Carly Rodriguez, MPH, PhD Candidate in Epidemiology, Boston University School of Public Health on Approaches for improving inference from observational multi-drug resistant tuberculosis (MDR-TB) treatment cohorts.

From our October 2019 Newsletter

The WHO Global Tuberculosis Report 2019 is Out

The WHO 2019 Global Tuberculosis Report has recently been published. It was found that the global MDR-TB epidemic increased by approximately half a million new cases of rifampin-resistant TB (of which 78% had multidrug-resistant TB) in 2018. Check out the link to the full global TB report 2019 below, and other recent news in DR-TB.
1. Global Tuberculosis Report 2019
2. Global campaign launched urging Johnson & Johnson to reduce price of bedaquiline
3. TB drug delamanid must be more affordable and made available in more countries
4. DR-TB Drugs Under the Microscope, 6th edition

From our September 2019 Newsletter

News

Below is the most recent State of the Art article from IJTLD, which discusses the use of palliative care and symptom relief (PCSR) for people affected by MDR-TB.
1. Palliative care and symptom relief for people affected by multi-drug resistant tuberculosis
Below is the new 2019 Lancet tuberculosis series presenting how the diagnosis of MDR-TB can be improved, how drug regimens can best be used to treat and applied to different populations, and how MDR-TB can be managed in the future.
2. The Lancet Tuberculosis 2019

FDA approves new drug for treatment-resistant forms of tuberculosis that affects the lungs

FDA approves new drug for treatment-resistant forms of tuberculosis that affects the lungs

Posted on 08/15/19

The FDA has approved a new drug for highly-resistant forms of drug-resistant tuberculosis. Developed by the non-profit TB alliance, Pretomanid has been approved to be used in a combination regimen with bedaquiline and linezolid for people with MDR-TB and XDR-TB.

From our August 2019 Newsletter

News

Here are a few items that address the exciting news about the FDA approval of pretomanid in the BPaL regimen; describe concern about the standard of the research that led to its approval, the regulatory precedent it sets; and highlight uncertainty around its affordability and access.

1. FDA approves new drug for treatment-resistant forms of tuberculosis that affects the lungs
2. New tuberculosis medicine studied in South Africa approved in United States
3. New Drug Could Be Game Changer For Drug-Resistant TB. But A Question Looms